Here’s what you should know.
1. Biolase conducted the study at Washington University in St. Louis. Researchers measured kidney function in health subjects to those with Stage 4 chronic kidney disease.
2. The company used its Transdermal Glomerular Filtration Rate Monitor. The system employs an optical skin sensor and a fluorescent tracer agent to provide physicians with real-time kidney monitoring.
3. MediBeacon CEO Steve Hanley said, “Completion of our clinical study on patients with impaired kidney function represents an important milestone. “
4. MediBeacon is conducting a multicenter, international study of the monitor in the fourth quarter of 2017.
More articles on improving health:
Only 31% of patients support surgeons performing overlapping surgeries: 4 things to know
20 US regions with the most & least medical debt
10 things to know about Regent Surgical Health
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
